Clinical Trial

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-22
notable Trial sites expanded: 1 -> 5 locations 2026-04-22
Trial Details
NCT Number NCT07008378
Lead Sponsor Genentech, Inc.
Collaborators: Poseida Therapeutics, Inc., a member of the Roche Group
Conditions Multiple Sclerosis
Enrollment 60 participants
Start Date 2025-10-15
Primary Completion 2032-08-31 (estimated)
Study Completion 2032-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15